Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Ciforadenant · 2 trials · 3 indications
Incidence of treatment-emergent adverse events, as assessed by NCI CTCAE v.5
| Arm | Type | Description |
|---|---|---|
| Ciforadenant in combination with daratumumab | EXPERIMENTAL | Ciforadenant 100 mg orally twice daily in combination with daratumumab IV 16 mg/kg. |
| Cohort 1 - Closed | EXPERIMENTAL | Ciforadenant |
| Cohort 2 - Closed | EXPERIMENTAL | Ciforadenant |
| Cohort 3 - Closed | EXPERIMENTAL | Ciforadenant |
| Cohort 4 | EXPERIMENTAL | Ciforadenant + atezolizumab |
| Cohort 5 - Closed | EXPERIMENTAL | Ciforadenant |
| Name | Type | Description |
|---|---|---|
| Ciforadenant | DRUG | 100 mg orally twice daily for 28-day cycles |
| daratumumab | DRUG | 16 mg/kg administered intravenously as follows based on 28-day cycles: * Cycles 1 - 2: Days 1, 8, 15, and 22 * Cycles 3 - 6: Days 1 and 15 * Cycles 7 - 24: Day 1 |
| Ciforadenant + atezolizumab | DRUG | Ciforadenant 100 mg orally twice daily in combination with atezolizumab intravenously. |
Inclusion Criteria: * Relapsed or refractory myeloma. * Must have been exposed to at least 2 cycles of an IMiD containing regimen and PI containing regimen and must be refractory to at least one of the two. * Must have completed and tolerated 2 cycles of daratumumab or other anti-CD38 targeting ant...
Top 20 of 25 competitors
Ciforadenant is an investigational small molecule being studied for the treatment of Multiple Myeloma and Renal Cell Cancer. It is being developed by Corvus Pharmaceuticals, Inc. (CRVS) and is currently in Phase 1 clinical development.
Ciforadenant is an investigational small molecule being developed for oncology indications. Its specific molecular target has not been disclosed in the available information.
Ciforadenant is being developed by Corvus Pharmaceuticals, Inc., a biopharmaceutical company traded on the stock exchange under the ticker symbol CRVS.
Ciforadenant is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. Clinical trials are ongoing to evaluate its safety and efficacy.
Ciforadenant has been studied in two Phase 1 clinical trials. NCT02655822 evaluated ciforadenant alone and in combination with atezolizumab in advanced cancers, including renal cell cancer. NCT04280328 studied ciforadenant in combination with daratumumab in patients with relapsed or refractory multiple myeloma.
Ciforadenant is not known to have any alternative names. It is a unique investigational compound being developed by Corvus Pharmaceuticals.